An activation-defective mutant of the human cytomegalovirus IE2p86 protein inhibits NF-kappaB-mediated stimulation of the human interleukin-6 promoter

J Gen Virol. 2007 Sep;88(Pt 9):2435-2440. doi: 10.1099/vir.0.82925-0.

Abstract

The IE2p86 protein of human cytomegalovirus is an essential activator of early- and late-phase viral gene expression. Whilst IE2p86 activates expression of a number of cellular genes, it also represses certain cellular genes, particularly those activated by nuclear factor kappaB (NF-kappaB). As the interleukin-6 (IL-6) promoter can be activated by both NF-kappaB and IE2p86, it was examined whether there is competition between these two factors. Here, it is reported that both wild-type and mutant IE2p86 can block activation of the IL-6 promoter in response to interleukin-1beta. By using an artificial activator in which the activation domain of NF-kappaB is directed to the promoter by the GAL4 DNA-binding domain, it is shown that the mutant form of IE2p86 can inhibit NF-kappaB-mediated activation at a step subsequent to promoter recruitment. These data therefore suggest a novel mechanism for inhibition of NF-kappaB by IE2p86.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cytomegalovirus / genetics*
  • Gene Expression Regulation / immunology
  • Gene Expression Regulation, Viral*
  • Glioblastoma
  • Humans
  • Immediate-Early Proteins / genetics*
  • Immediate-Early Proteins / pharmacology*
  • Interleukin-6 / genetics*
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / pharmacology
  • Promoter Regions, Genetic*
  • Trans-Activators / genetics*
  • Trans-Activators / pharmacology*
  • Transfection

Substances

  • IE2 protein, Cytomegalovirus
  • Immediate-Early Proteins
  • Interleukin-6
  • NF-kappa B
  • Trans-Activators